Sorry, which conspiracy ridden drek website published this particular nonsense?
I especially like the use of “No one knows”! Ooooo SPOOKY! Yes, no one knows if drinking a cup of tea will cause your eyes to explode. Probably not, but hey “NO ONE KNOOOOWWWWWWSSSS”. Throw in some scary sounding medical terms and you’ve got yourself a winner!
Where it falls down is when it says “An adjuvant is being included in the vaccine”. Whoops! The Pfizer and Moderna vaccines include no adjuvants. Almost had it!
But wait, there’s more! “The dead lab animal victims in earlier studies...” Whoops! Neither the animals in the clinical studies nor any of the human participants in the Phase 1, Phase 2, or Phase 3 human trials died. None.
I always prefer my fantasy writing to include space ships and other fun far-away things. I think if you’re going to write pure fiction, at least make it entertaining.
Your writing borders on hypomanic if not manic. A little defensive, are you?
Sample references (first 61 from 2020 Nature article).
“Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Wen Shi Lee, Adam K. Wheatley, […]Brandon J. DeKosky
Nature Microbiology volume 5, pages1185–1191(2020)”
References
1.
Zhou, Y. et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 6, 14 (2020).
CAS
PubMed
PubMed Central
Google Scholar
2.
Lu, R. et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 395, 565–574 (2020).
CAS
PubMed
PubMed Central
Google Scholar
3.
Lam, T. T. et al. Identifying SARS-CoV-2 related coronaviruses in Malayan pangolins. Nature 583, 282–285 (2020).
CAS
PubMed
Google Scholar
4.
Hoffmann, M. et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280 (2020).
CAS
PubMed
PubMed Central
Google Scholar
5.
Yan, R. et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 367, 1444–1448 (2020).
CAS
PubMed
PubMed Central
Google Scholar
6.
Daly, J. L. et al. Neuropilin-1 is a host factor for SARS-CoV-2 infection. Preprint at https://www.biorxiv.org/content/10.1101/2020.06.05.134114v1 (2020).
7.
Cantuti-Castelvetri, L. et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and provides a possible pathway into the central nervous system. Preprint at https://www.biorxiv.org/content/10.1101/2020.06.07.137802v1 (2020).
8.
Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260–1263 (2020).
CAS
PubMed
PubMed Central
Google Scholar
9.
Kim, H. W. et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am. J. Epidemiol. 89, 422–434 (1969).
CAS
PubMed
Google Scholar
10.
Graham, B. S. Vaccines against respiratory syncytial virus: the time has finally come. Vaccine 34, 3535–3541 (2016).
PubMed
PubMed Central
Google Scholar
11.
Nader, P. R., Horwitz, M. S. & Rousseau, J. Atypical exanthem following exposure to natural measles: eleven cases in children previously inoculated with killed vaccine. J. Pediatr. 72, 22–28 (1968).
Google Scholar
12.
Polack, F. P. Atypical measles and enhanced respiratory syncytial virus disease (ERD) made simple. Pediatr. Res. 62, 111–115 (2007).
PubMed
Google Scholar
13.
Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745–748 (2010).
CAS
PubMed
Google Scholar
14.
Sridhar, S. et al. Effect of dengue serostatus on dengue vaccine safety and efficacy. N. Engl. J. Med. 379, 327–340 (2018).
PubMed
Google Scholar
15.
Hohdatsu, T. et al. Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. J. Vet. Med. Sci. 60, 49–55 (1998).
CAS
PubMed
Google Scholar
16.
Halstead, S. B. & O’Rourke, E. J. Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody. J. Exp. Med. 146, 201–217 (1977).
CAS
PubMed
PubMed Central
Google Scholar
17.
Vennema, H. et al. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization. J. Virol. 64, 1407–1409 (1990).
CAS
PubMed
PubMed Central
Google Scholar
18.
Hohdatsu, T., Nakamura, M., Ishizuka, Y., Yamada, H. & Koyama, H. A study on the mechanism of antibody-dependent enhancement of feline infectious peritonitis virus infection in feline macrophages by monoclonal antibodies. Arch. Virol. 120, 207–217 (1991).
CAS
PubMed
PubMed Central
Google Scholar
19.
Weiss, R. C. & Scott, F. W. Antibody-mediated enhancement of disease in feline infectious peritonitis: comparisons with dengue hemorrhagic fever. Comp. Immunol. Microbiol. Infect. Dis. 4, 175–189 (1981).
CAS
PubMed
PubMed Central
Google Scholar
20.
Ye, Z. W. et al. Antibody-dependent cell-mediated cytotoxicity epitopes on the hemagglutinin head region of pandemic H1N1 influenza virus play detrimental roles in H1N1-infected mice. Front. Immunol. 8, 317 (2017).
PubMed
PubMed Central
Google Scholar
21.
Winarski, K. L. et al. Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics. Proc. Natl Acad. Sci. USA 116, 15194–15199 (2019).
CAS
PubMed
Google Scholar
22.
Polack, F. P. et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J. Exp. Med. 196, 859–865 (2002).
CAS
PubMed
PubMed Central
Google Scholar
23.
Polack, F. P., Hoffman, S. J., Crujeiras, G. & Griffin, D. E. A role for nonprotective complement-fixing antibodies with low avidity for measles virus in atypical measles. Nat. Med. 9, 1209–1213 (2003).
CAS
PubMed
Google Scholar
24.
Gao, T. et al. Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. Preprint at https://www.medrxiv.org/content/10.1101/2020.03.29.20041962v3 (2020).
25.
Gralinski, L. E. et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 9, e01753-18 (2018).
PubMed
PubMed Central
Google Scholar
26.
Larsen, M. D. et al. Afucosylated immunoglobulin G responses are a hallmark of enveloped virus infections and show an exacerbated phenotype in COVID-19. Preprint at https://www.biorxiv.org/content/10.1101/2020.05.18.099507v1 (2020).
27.
Chakraborty, S. et al. Symptomatic SARS-CoV-2 infections display specific IgG Fc structures. Preprint at https://www.medrxiv.org/content/10.1101/2020.05.15.20103341v1 (2020).
28.
Hiatt, A. et al. Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proc. Natl Acad. Sci. USA 111, 5992–5997 (2014).
CAS
PubMed
Google Scholar
29.
Zeitlin, L. et al. Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant. Proc. Natl Acad. Sci. USA 108, 20690–20694 (2011).
CAS
PubMed
Google Scholar
30.
Wang, T. T. et al. IgG antibodies to dengue enhanced for FcγRIIIA binding determine disease severity. Science 355, 395–398 (2017).
CAS
PubMed
PubMed Central
Google Scholar
31.
Hui, K. P. Y. et al. Tropism, replication competence, and innate immune responses of the coronavirus SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures. Lancet Respir. Med. 8, 687–695 (2020).
CAS
PubMed
PubMed Central
Google Scholar
32.
Yip, M. S. et al. Antibody-dependent infection of human macrophages by severe acute respiratory syndrome coronavirus. Virol. J. 11, 82 (2014).
PubMed
PubMed Central
Google Scholar
33.
Robinson, W. E. Jr, Montefiori, D. C. & Mitchell, W. M. Antibody-dependent enhancement of human immunodeficiency virus type 1 infection. Lancet 1, 790–794 (1988).
PubMed
Google Scholar
34.
Robinson, W. E. Jr et al. Antibody-dependent enhancement of human immunodeficiency virus type 1 (HIV-1) infection in vitro by serum from HIV-1-infected and passively immunized chimpanzees. Proc. Natl Acad. Sci. USA 86, 4710–4714 (1989).
PubMed
Google Scholar
35.
Takada, A., Watanabe, S., Okazaki, K., Kida, H. & Kawaoka, Y. Infectivity-enhancing antibodies to Ebola virus glycoprotein. J. Virol. 75, 2324–2330 (2001).
CAS
PubMed
PubMed Central
Google Scholar
36.
Takada, A., Feldmann, H., Ksiazek, T. G. & Kawaoka, Y. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77, 7539–7544 (2003).
CAS
PubMed
PubMed Central
Google Scholar
37.
Ochiai, H. et al. Infection enhancement of influenza A NWS virus in primary murine macrophages by anti-hemagglutinin monoclonal antibody. J. Med. Virol. 36, 217–221 (1992).
CAS
PubMed
Google Scholar
38.
Sariol, C. A., Nogueira, M. L. & Vasilakis, N. A tale of two viruses: does heterologous flavivirus immunity enhance Zika disease? Trends Microbiol. 26, 186–190 (2018).
CAS
PubMed
Google Scholar
39.
Wan, Y. et al. Molecular mechanism for antibody-dependent enhancement of coronavirus entry. J. Virol. 94, e02015-19 (2020).
PubMed
PubMed Central
Google Scholar
40.
Jaume, M. et al. Anti-severe acute respiratory syndrome coronavirus spike antibodies trigger infection of human immune cells via a pH- and cysteine protease-independent FcγR pathway. J. Virol. 85, 10582–10597 (2011).
CAS
PubMed
PubMed Central
Google Scholar
41.
Cheung, C. Y. et al. Cytokine responses in severe acute respiratory syndrome coronavirus-infected macrophages in vitro: possible relevance to pathogenesis. J. Virol. 79, 7819–7826 (2005).
CAS
PubMed
PubMed Central
Google Scholar
42.
Yip, M. S. et al. Antibody-dependent enhancement of SARS coronavirus infection and its role in the pathogenesis of SARS. Hong Kong Med. J. 22, 25–31 (2016).
CAS
PubMed
Google Scholar
43.
Ana-Sosa-Batiz, F. et al. Influenza-specific antibody-dependent phagocytosis. PLoS ONE 11, e0154461 (2016).
PubMed
PubMed Central
Google Scholar
44.
Yasui, F. et al. Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus. Virology 454–455, 157–168 (2014).
PubMed
Google Scholar
45.
Zhou, J. et al. Active replication of Middle East respiratory syndrome coronavirus and aberrant induction of inflammatory cytokines and chemokines in human macrophages: implications for pathogenesis. J. Infect. Dis. 209, 1331–1342 (2014).
CAS
PubMed
Google Scholar
46.
Ho, M. S. et al. Neutralizing antibody response and SARS severity. Emerg. Infect. Dis. 11, 1730–1737 (2005).
CAS
PubMed
PubMed Central
Google Scholar
47.
Zhao, J. et al. Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa344 (2020).
48.
Liu, Y. et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect. Dis. 20, 656–657 (2020).
CAS
PubMed
PubMed Central
Google Scholar
49.
Zheng, S. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January–March 2020: retrospective cohort study. BMJ 369, m1443 (2020).
PubMed
PubMed Central
Google Scholar
50.
Long, Q. X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 26, 1200–1204 (2020).
CAS
PubMed
Google Scholar
51.
Sekine, T. et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell https://doi.org/10.1016/j.cell.2020.08.017 (2020).
52.
Mathew, D., Giles, J. R., Baxter, A. E., Oldridge, D. A. & Greenplate, A. R. Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications. Science https://doi.org/10.1126/science.abc8511 (2020).
53.
Tetro, J. A. Is COVID-19 receiving ADE from other coronaviruses? Microbes Infect. 22, 72–73 (2020).
CAS
PubMed
PubMed Central
Google Scholar
54.
Khan, S. et al. Analysis of serologic cross-reactivity between common human coronaviruses and SARS-CoV-2 using coronavirus antigen microarray. Preprint at https://www.biorxiv.org/content/10.1101/2020.03.24.006544v1 (2020).
55.
Tseng, C. T. et al. Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS ONE 7, e35421 (2012).
CAS
PubMed
PubMed Central
Google Scholar
56.
Deming, D. et al. Vaccine efficacy in senescent mice challenged with recombinant SARS-CoV bearing epidemic and zoonotic spike variants. PLoS Med. 3, e525 (2006).
PubMed
PubMed Central
Google Scholar
57.
Bolles, M. et al. A double-inactivated severe acute respiratory syndrome coronavirus vaccine provides incomplete protection in mice and induces increased eosinophilic proinflammatory pulmonary response upon challenge. J. Virol. 85, 12201–12215 (2011).
CAS
PubMed
PubMed Central
Google Scholar
58.
Yasui, F. et al. Prior immunization with severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV) nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J. Immunol. 181, 6337–6348 (2008).
CAS
PubMed
Google Scholar
59.
Agrawal, A. S. et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum. Vaccin. Immunother. 12, 2351–2356 (2016).
PubMed
PubMed Central
Google Scholar
60.
Weingartl, H. et al. Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J. Virol. 78, 12672–12676 (2004).
CAS
PubMed
PubMed Central
Google Scholar
61.
Czub, M., Weingartl, H., Czub, S., He, R. & Cao, J. Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets. Vaccine 23, 2273–2279 (2005).